Lotus Biotech Development Corp.: 10-K filed 2013-07-01
What Lotus Biotech Development Corp. reported in its annual report filed 2013-07-01 (fiscal FY 2012): 9 published measures, 23 facts as tagged in accession 0001002014-13-000281.
This filing
- Form
- 10-K (annual report)
- Filed
- 2013-07-01
- Fiscal period
- fiscal FY 2012
- Accession
- 0001002014-13-000281 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lotus Biotech Development Corp. filings.
Reported measures
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | -9,277 | USD | |
| At 2012-03-31 | -51,389 | USD | |
| At 2010-03-23 | -15,500 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 4,069 | USD | |
| At 2012-03-31 | 411 | USD | |
| At 2011-03-31 | 50 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-04-01 to 2013-03-31 | -62,138 | USD | 365 |
| 2011-03-24 to 2013-03-31 | -113,577 | USD | 739 |
| 2011-04-01 to 2012-03-31 | -35,889 | USD | 366 |
| 2010-03-24 to 2011-03-31 | -15,550 | USD | 373 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-04-01 to 2013-03-31 | -72,204 | USD | 365 |
| 2011-03-24 to 2013-03-31 | -91,793 | USD | 739 |
| 2011-04-01 to 2012-03-31 | -4,589 | USD | 366 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-04-01 to 2013-03-31 | 75,862 | USD | 365 |
| 2011-03-24 to 2013-03-31 | 116,296 | USD | 739 |
| 2011-04-01 to 2012-03-31 | 4,950 | USD | 366 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-03-24 to 2013-03-31 | -20,434 | USD | 739 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 4,069 | USD | |
| At 2012-03-31 | 411 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 13,346 | USD | |
| At 2012-03-31 | 51,800 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | -32,600 | USD | |
| At 2012-03-31 | -10,852 | USD |
Inspect the source
- Entity
- Lotus Biotech Development Corp. / CIK 0001520592
- Captured
- SEC response SHA-256
bb66e059f830b74605654323cb1a568c3bcc71a4f51b0be18e8739c2eaf2c9b9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001520592.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))